GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (OTCPK:MDNAF) » Definitions » 1-Year ROIIC %

Medicenna Therapeutics (Medicenna Therapeutics) 1-Year ROIIC % : 29,625.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Medicenna Therapeutics 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Medicenna Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 29,625.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Medicenna Therapeutics's 1-Year ROIIC % or its related term are showing as below:

MDNAF's 1-Year ROIIC % is ranked better than
99.46% of 1476 companies
in the Biotechnology industry
Industry Median: -2.815 vs MDNAF: 29625.00

Medicenna Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for Medicenna Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics 1-Year ROIIC % Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only 812.65 1,459.75 21,785.71 -3,115.34 -2,581.59

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,729.21 -2,581.59 -83,100.00 33,825.00 29,625.00

Competitive Comparison of Medicenna Therapeutics's 1-Year ROIIC %

For the Biotechnology subindustry, Medicenna Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's 1-Year ROIIC % falls into.



Medicenna Therapeutics 1-Year ROIIC % Calculation

Medicenna Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -13.106 (Dec. 2023) - -12.533 (Dec. 2022) )/( 0.042999999999999 (Dec. 2023) - 0.046000000000003 (Dec. 2022) )
=-0.573/-0.0030000000000037
=19,100.00%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Medicenna Therapeutics  (OTCPK:MDNAF) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Medicenna Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (Medicenna Therapeutics) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.